Iatreia (Apr 2020)

Efficacy of cannabinoids in pharmacoresistant epilepsy: A narrative review of the literature

  • Ferreiros, Alexandra,
  • Beltrán-Carrascal, Elkin,
  • Restrepo, Paula,
  • Pantoja, Camila ,
  • Castañeda-Cardona, Camilo,
  • Lasalvia, Pieralessandro,
  • Van der Werf, Laura,
  • Nariño, Daniel,
  • Rosselli, Diego

DOI
https://doi.org/10.17533/udea.iatreia.42
Journal volume & issue
Vol. 33, no. 2
pp. 167 – 176

Abstract

Read online

Epilepsy is a common neurological disorder that affects approximately 1% of the world’s pop7u-lation. About one third of those patients suffer from treatment-resistant epilepsy (TRE8), defined as failure to stop seizures despite adequate trials of at least two medications at therapeutic dosa-ges. There has been a growing interest in the development of novel antiepileptic drugs with diffe-rent mechanisms of action. This narrative review, based on 42 references retrieved from Scopus and Medline, discusses the scientific data from human and animal studies regarding the efficacy of cannabis-based treatment for epilepsy. Benefits have been described in pre-clinical and cli-nical studies in children, but ongoing research will clarify the real role of cannabinoids in TRE.

Keywords